iRadimed (NASDAQ:IRMD – Get Free Report) and Beta Bionics (NASDAQ:BBNX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.
Insider and Institutional Ownership
92.3% of iRadimed shares are owned by institutional investors. 36.8% of iRadimed shares are owned by insiders. Comparatively, 5.3% of Beta Bionics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares iRadimed and Beta Bionics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iRadimed | $86.28 million | 13.77 | $22.48 million | $1.83 | 50.79 |
| Beta Bionics | $100.25 million | 5.21 | -$73.20 million | ($1.51) | -7.76 |
iRadimed has higher earnings, but lower revenue than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for iRadimed and Beta Bionics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iRadimed | 0 | 1 | 3 | 1 | 3.00 |
| Beta Bionics | 1 | 3 | 7 | 1 | 2.67 |
iRadimed presently has a consensus target price of $120.00, indicating a potential upside of 29.12%. Beta Bionics has a consensus target price of $20.00, indicating a potential upside of 70.65%. Given Beta Bionics’ higher possible upside, analysts clearly believe Beta Bionics is more favorable than iRadimed.
Profitability
This table compares iRadimed and Beta Bionics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iRadimed | 27.36% | 24.48% | 21.25% |
| Beta Bionics | -60.27% | -23.00% | -20.55% |
Volatility and Risk
iRadimed has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Beta Bionics has a beta of 3.29, indicating that its share price is 229% more volatile than the S&P 500.
Summary
iRadimed beats Beta Bionics on 10 of the 14 factors compared between the two stocks.
About iRadimed
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
